BACKGROUND: The National Institutes of Health Consensus Conference proposed the term "overlap" graft-versus-host disease to describe the situation when both acute and chronic graft-versus-host disease are present. DESIGN AND METHODS: We examined whether the overlap subtype of graft-versus-host disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to "classic" chronic graft-versus-host disease without any acute features. RESULTS: Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft-versus-host disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment (P=0.01), were more likely to be incident cases (P<0.001), and had a lower platelet count at onset of the graft-versus-host disease (P<0.001). Patients with overlap graft-versus-host disease had significantly greater functional impairment measured by a 2-minute walk test, higher symptom burden and lower Human Activity Profile scores. Quality of life was similar, except patients with overlap graft-versus-host disease had worse social functioning, assessed by the Short Form-36. Multivariable analysis utilizing time-varying covariates demonstrated that the overlap subtype of graft-versus-host disease was associated with worse overall survival (HR 2.1, 95% CI 1.1-4.7; P=0.03) and higher non-relapse mortality (HR 2.8, 95% CI 1.2-8.3; P=0.02) than classic chronic graft-versus-host disease. CONCLUSIONS: These findings suggest that the presence of acute features in patients with chronic graft-versus-host disease is a marker of adverse prognosis, greater functional impairment, and higher symptom burden.
BACKGROUND: The National Institutes of Health Consensus Conference proposed the term "overlap" graft-versus-host disease to describe the situation when both acute and chronic graft-versus-host disease are present. DESIGN AND METHODS: We examined whether the overlap subtype of graft-versus-host disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to "classic" chronic graft-versus-host disease without any acute features. RESULTS: Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft-versus-host disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment (P=0.01), were more likely to be incident cases (P<0.001), and had a lower platelet count at onset of the graft-versus-host disease (P<0.001). Patients with overlap graft-versus-host disease had significantly greater functional impairment measured by a 2-minute walk test, higher symptom burden and lower Human Activity Profile scores. Quality of life was similar, except patients with overlap graft-versus-host disease had worse social functioning, assessed by the Short Form-36. Multivariable analysis utilizing time-varying covariates demonstrated that the overlap subtype of graft-versus-host disease was associated with worse overall survival (HR 2.1, 95% CI 1.1-4.7; P=0.03) and higher non-relapse mortality (HR 2.8, 95% CI 1.2-8.3; P=0.02) than classic chronic graft-versus-host disease. CONCLUSIONS: These findings suggest that the presence of acute features in patients with chronic graft-versus-host disease is a marker of adverse prognosis, greater functional impairment, and higher symptom burden.
Authors: Gorgun Akpek; Stephanie J Lee; Mary E Flowers; Steven Z Pavletic; Mukta Arora; Shing Lee; Steven Piantadosi; Katherine A Guthrie; James C Lynch; Alessandra Takatu; Mary M Horowitz; Joseph H Antin; Daniel J Weisdorf; Paul J Martin; Georgia B Vogelsang Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Joseph Pidala; Brenda F Kurland; Xiaoyu Chai; Georgia Vogelsang; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; Navneet Majhail; Stephanie J Lee Journal: Haematologica Date: 2011-06-17 Impact factor: 9.941
Authors: Sally Arai; Madan Jagasia; Barry Storer; Xiaoyu Chai; Joseph Pidala; Corey Cutler; Mukta Arora; Daniel J Weisdorf; Mary E D Flowers; Paul J Martin; Jeanne Palmer; David Jacobsohn; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee Journal: Blood Date: 2011-07-26 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Joseph Pidala; Jongphil Kim; Melissa Alsina; Ernesto Ayala; Brian C Betts; Hugo F Fernandez; Teresa Field; Heather Jim; Mohamed A Kharfan-Dabaja; Frederick L Locke; Asmita Mishra; Taiga Nishihori; Leonel Ochoa-Bayona; Lia Perez; Marcie Riches; Claudio Anasetti Journal: Haematologica Date: 2015-04-03 Impact factor: 9.941
Authors: Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2014-12-18 Impact factor: 5.742
Authors: Jocelyn S Gandelman; John Zic; Anna K Dewan; Stephanie J Lee; Mary Flowers; Corey Cutler; Joseph Pidala; Heidi Chen; Madan H Jagasia; Eric R Tkaczyk Journal: Biol Blood Marrow Transplant Date: 2018-09-13 Impact factor: 5.742
Authors: M Arora; J Pidala; C S Cutler; X Chai; B Kurland; D A Jacobsohn; S Z Pavletic; J Palmer; G Vogelsang; M Jagasia; K Schultz; S J Lee Journal: Leukemia Date: 2012-10-10 Impact factor: 11.528